<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162863</url>
  </required_header>
  <id_info>
    <org_study_id>08-028LUB</org_study_id>
    <nct_id>NCT01162863</nct_id>
  </id_info>
  <brief_title>Effects of Lubiprostone on Gastrointestinal Transit &amp; pH in Irritable Bowel Syndrome (IBS) With Constipation</brief_title>
  <official_title>A Pilot Study to Assess the Effects of Lubiprostone on Gastrointestinal and Colonic Motility and pH in Patients With the Irritable Bowel Syndrome and Constipation (IBS-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <brief_summary>
    <textblock>
      Irritable bowel syndrome (IBS) is a common disorder which presents with abdominal pain or&#xD;
      discomfort in association with altered bowel habit. IBS is further subcategorized as three&#xD;
      types according to the predominant bowel movement pattern: IBS with constipation (IBS-C), IBS&#xD;
      with diarrhea (IBS-D), and mixed-IBS (IBS-M). The exact causes of IBS remain incompletely&#xD;
      understood, but proposed mechanisms include abnormal motility, visceral hypersensitivity,&#xD;
      abnormal brain-gut interactions, psychological distress, and altered GI tract motility.&#xD;
&#xD;
      Lubiprostone, a novel drug that works by activating the colonic Chloride channel type&#xD;
      2(ClC-2), has been approved for use in patients with chronic idiopathic constipation and&#xD;
      recently approved for the treatment of IBS-C in women aged 18 and older. By activating the&#xD;
      ClC-2 chloride channel in the colon, lubiprostone allows more fluid secretion into the&#xD;
      intestinal lumen which leads to softer stool consistency. In phase III clinical trials,&#xD;
      patients with IBS-C receiving lubiprostone have reported improvements in many symptoms such&#xD;
      as abdominal pain and constipation. However, there is limited physiologic data to explain how&#xD;
      exactly lubiprostone improves IBS-C symptoms.&#xD;
&#xD;
      The Smartpill is a novel non-digestible capsule that is capable of measuring intraluminal pH,&#xD;
      pressure, and temperature in the gastrointestinal (GI) tract. Smartpill has been shown to&#xD;
      accurately measure whole gut as well as regional (i.e. stomach, small bowel, colon) transit&#xD;
      time.&#xD;
&#xD;
      The primary aim of this study is to determine the effects of lubiprostone on whole GI tract&#xD;
      transit, colonic transit, motility, and intraluminal pH in patients with IBS-C through&#xD;
      evaluation with the Smartpill. The investigators propose to study the effect of lubiprostone&#xD;
      vs. placebo on these parameters, and secondarily to evaluate changes in these parameters with&#xD;
      differing doses of lubiprostone.&#xD;
&#xD;
      The investigators hypothesize that lubiprostone will increase whole GI and colonic transit&#xD;
      compared to placebo in patient with IBS. the investigators do not expect a change in&#xD;
      intraluminal pH with lubiprostone compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline</measure>
    <time_frame>21-28 days</time_frame>
    <description>Change in gastric emptying time, small bowel transit time, colon transit time and whole gut transit time measured in hours based on a measurement done at baseline and then again at 3 weeks into the intervention within each treatment arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Small Bowel pH and Colon pH From Baseline</measure>
    <time_frame>21-28 days</time_frame>
    <description>Change in the mean pH of the small intestine and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Motility Pattern of the Small Bowel and Colon From Baseline as Defined by the Motility Index</measure>
    <time_frame>21-28 days</time_frame>
    <description>Change in the motility index defined as the natural log [(sum of pressure amplitudes times the number of contractions) + 1] for the small bowel and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Lubiprostone 8 mcg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lubiprostone 24 mcg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <description>lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days</description>
    <arm_group_label>Lubiprostone 24 mcg QD</arm_group_label>
    <arm_group_label>Lubiprostone 8 mcg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>taken orally for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smartpill wireless motility capsule</intervention_name>
    <description>Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
    <arm_group_label>Lubiprostone 24 mcg QD</arm_group_label>
    <arm_group_label>Lubiprostone 8 mcg BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females &gt;18 years of age&#xD;
&#xD;
          -  Meet Rome III criteria for IBS[2]:&#xD;
&#xD;
               -  Recurrent abdominal pain or discomfort at least 3 days per month in the last 3&#xD;
                  months associated with 2 or more of the following:&#xD;
&#xD;
                    1. Improvement with defecation&#xD;
&#xD;
                    2. Onset associated with a change in frequency&#xD;
&#xD;
                    3. Onset associated with a change in form (appearance) of stool&#xD;
&#xD;
               -  *Criteria fulfilled for the last 3 months with symptom onset at least 6 months&#xD;
                  prior to diagnosis&#xD;
&#xD;
          -  Fulfill the Rome III stool consistency criteria for IBS-C[2]&#xD;
&#xD;
               -  Hard or lumpy stools for &gt;25% of bowel movements&#xD;
&#xD;
               -  Loose (mushy) or watery stools for &lt;25% of bowel movements&#xD;
&#xD;
          -  Capable of independently completing all requirements of the study including returning&#xD;
             for required visits&#xD;
&#xD;
          -  Able to provide written informed consent for study participation&#xD;
&#xD;
          -  Willing to discontinue prohibited medications during study participation&#xD;
&#xD;
          -  Documentation of a normal colonoscopy within last 5 years if over age 50 years (or&#xD;
             sigmoidoscopy if less than age 50)&#xD;
&#xD;
          -  Documentation of normal thyroid stimulating hormone(TSH) level, complet blood count&#xD;
             (CBC) and electrolyte panel within prior 3 years&#xD;
&#xD;
          -  Females of childbearing potential must have a negative urine or serum pregnancy test&#xD;
             at screening&#xD;
&#xD;
          -  Females of childbearing potential must use an effective means of contraception during&#xD;
             the course of the study&#xD;
&#xD;
               -  Hormonal (oral, injectable, implantable, cervical/vaginal rings or patches)&#xD;
&#xD;
               -  Double-barrier (condoms and/or diaphragm with spermicides) or intrauterine&#xD;
                  devices provided under the care of a health care professional&#xD;
&#xD;
               -  Abstinence, in this case documentation of counseling will be recorded&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to understand or provide written informed consent&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Patients with IBS-D, IBS-M or unsubtyped IBS by Rome III criteria[2]&#xD;
&#xD;
          -  IBS with diarrhea (IBS-D)&#xD;
&#xD;
               1. Loose (mushy) or watery stools for &gt;25% of bowel movements&#xD;
&#xD;
               2. Hard or lumpy stools for &lt;25% of bowel movements&#xD;
&#xD;
          -  Mixed IBS (IBS-M)&#xD;
&#xD;
               1. Hard or lumpy stools &gt;25% of bowel movements&#xD;
&#xD;
               2. Loose (mushy) or watery stools for &gt;25% of bowel movements&#xD;
&#xD;
          -  Unsubtyped IBS&#xD;
&#xD;
             1. Insufficient abnormality of stool pattern to meet criteria for IBS-C, IBS-D or&#xD;
             IBS-M&#xD;
&#xD;
          -  Documented allergy or intolerance to lubiprostone&#xD;
&#xD;
          -  Failure of balloon expulsion test&#xD;
&#xD;
               -  Inability to expel 50cc balloon within 1 minute&#xD;
&#xD;
          -  Use of drugs known to affect gastrointestinal motility&#xD;
&#xD;
               1. Laxatives (stable doses of fiber taken for minimum of 4 weeks will be allowed)&#xD;
&#xD;
                  Osmotic laxatives:&#xD;
&#xD;
                  Magnesium hydroxide, Polyethylene glycol,Lactulose, Sorbitol&#xD;
&#xD;
                  Stimulant laxatives:&#xD;
&#xD;
                  Bisacodyl, Anthraquinones (senna), Misoprostol&#xD;
&#xD;
               2. Prokinetic agents:&#xD;
&#xD;
                  Metoclopramide, domperidone, erythromycin&#xD;
&#xD;
               3. Anti-diarrheal agents:&#xD;
&#xD;
                  Loperamide, Diphenoxylate, Bismuth&#xD;
&#xD;
               4. Anti-spasmotics:&#xD;
&#xD;
                  Dicyclomine, Hyoscyamine&#xD;
&#xD;
               5. Opioid, narcotic, opioid/narcotic-containing analgesics:&#xD;
&#xD;
                  Morphine, Hydrocodone, Codeine, Methadone, Propoxyphene&#xD;
&#xD;
               6. Probiotics&#xD;
&#xD;
               7. Systemic antibiotics within last 3 months&#xD;
&#xD;
               8. Recently initiated antidepressants (stable dose for &gt;2 months for non-GI&#xD;
                  conditions will be allowed)&#xD;
&#xD;
               9. Benzodiazepines * Subjects taking prohibited medications will be required to stop&#xD;
                  these at the screening visit and remain off of them until completion of the&#xD;
                  study.&#xD;
&#xD;
          -  Initiation of dietary changes potentially altering bowel transit within 4 weeks&#xD;
&#xD;
          -  Comorbid medical problems that may affect gastrointestinal transit or motility&#xD;
&#xD;
               1. Previous surgery involving the stomach, small bowel or colon (prior appendectomy,&#xD;
                  cholecystectomy, polypectomy allowed)&#xD;
&#xD;
               2. Previous history of small bowel obstruction for any reason&#xD;
&#xD;
               3. History of any gastrointestinal malignancy&#xD;
&#xD;
               4. History of dyssynergic defecation&#xD;
&#xD;
               5. Unexplained nausea and vomiting&#xD;
&#xD;
               6. History of inflammatory bowel disease (Crohn's or ulcerative colitis)&#xD;
&#xD;
               7. History of microscopic colitis (lymphocytic or collagenous colitis)&#xD;
&#xD;
               8. History of Hirschsprung's disease&#xD;
&#xD;
               9. Severe or complicated diverticular disease&#xD;
&#xD;
              10. Chronic pancreatitis&#xD;
&#xD;
              11. History of celiac disease&#xD;
&#xD;
              12. History of eating disorders (anorexia nervosa or bulimia)&#xD;
&#xD;
              13. Cirrhosis&#xD;
&#xD;
              14. Chronic hepatitis B or C infection&#xD;
&#xD;
              15. HIV infection&#xD;
&#xD;
              16. Diabetes&#xD;
&#xD;
              17. Systemic sclerosis (scleroderma)&#xD;
&#xD;
              18. Amyloidosis&#xD;
&#xD;
              19. Untreated thyroid disease&#xD;
&#xD;
              20. Chronic pulmonary disease&#xD;
&#xD;
              21. Severe renal insufficiency or renal failure&#xD;
&#xD;
              22. Current or recent history (within last 6 months) of:&#xD;
&#xD;
                  Diverticulitis, Duodenal or gastric ulcer, Acute pancreatitis, Ileus&#xD;
&#xD;
          -  Contraindications to SmartPillÂ® (in addition to above):&#xD;
&#xD;
        Cardiac pacemaker, defibrillator, or other implanted electromagnetic device, Known Zenker's&#xD;
        diverticulum, Dysphagia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Saad</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <results_first_submitted>December 2, 2016</results_first_submitted>
  <results_first_submitted_qc>December 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2017</results_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Richard J. Saad, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>IBSC</keyword>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>60 adults were screened of whom 4 were screen failures.Of the 56 remaining study participants, 2 were unable to swallow the wireless motility capsule and 2 more dropped out of the study prior to randomization yielding 52 randomized participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: taken orally for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
        <group group_id="P2">
          <title>Lubiprostone 24 mcg QD</title>
          <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
        <group group_id="P3">
          <title>Lubiprostone 8 mcg BID</title>
          <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline data is given for those persons who actually completed the study, so the two people who dropped out were not included in the baseline measures. We determined this to be the more useful way to identify the effects of the three randomized procedures. Therefore the baseline data is based on the 50 participants who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: taken orally for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
        <group group_id="B2">
          <title>Lubiprostone 24 mcg QD</title>
          <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
        <group group_id="B3">
          <title>Lubiprostone 8 mcg BID</title>
          <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>mean age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="16.1"/>
                    <measurement group_id="B2" value="46.5" spread="18.7"/>
                    <measurement group_id="B3" value="37.2" spread="15.8"/>
                    <measurement group_id="B4" value="41.2" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline gastric emptying time</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.25" spread="5.52"/>
                    <measurement group_id="B2" value="3.18" spread="0.95"/>
                    <measurement group_id="B3" value="4.67" spread="3.47"/>
                    <measurement group_id="B4" value="4.01" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Small Bowel Transit time</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.84" spread="1.69"/>
                    <measurement group_id="B2" value="4.01" spread="1.02"/>
                    <measurement group_id="B3" value="4.81" spread="2.13"/>
                    <measurement group_id="B4" value="4.63" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Colon Transit Time</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.18" spread="16.46"/>
                    <measurement group_id="B2" value="44.61" spread="27.18"/>
                    <measurement group_id="B3" value="37.12" spread="30.04"/>
                    <measurement group_id="B4" value="38.15" spread="25.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Whole Gut Transit Time</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.47" spread="16.26"/>
                    <measurement group_id="B2" value="51.81" spread="26.78"/>
                    <measurement group_id="B3" value="47.0" spread="30.0"/>
                    <measurement group_id="B4" value="47.0" spread="24.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Small Bowel pH</title>
          <units>units on pH scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.82" spread="0.28"/>
                    <measurement group_id="B2" value="6.75" spread="0.34"/>
                    <measurement group_id="B3" value="6.77" spread="0.39"/>
                    <measurement group_id="B4" value="6.78" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Colon pH</title>
          <units>units on pH scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.56" spread="0.55"/>
                    <measurement group_id="B2" value="6.75" spread="0.34"/>
                    <measurement group_id="B3" value="6.47" spread="0.48"/>
                    <measurement group_id="B4" value="6.50" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Small Bowel Motility Index</title>
          <description>natural log [(sum of pressure amplitudes times the number of contractions) + 1] , resulting in a sort of units on a naturally derived scale</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.14" spread="1.66"/>
                    <measurement group_id="B2" value="12.80" spread="1.86"/>
                    <measurement group_id="B3" value="12.65" spread="2.26"/>
                    <measurement group_id="B4" value="12.86" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Colon Motility Index</title>
          <description>natural log [(sum of pressure amplitudes times the number of contractions) + 1]</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.26" spread="1.57"/>
                    <measurement group_id="B2" value="16.9" spread="2.14"/>
                    <measurement group_id="B3" value="16.17" spread="1.79"/>
                    <measurement group_id="B4" value="16.43" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline</title>
        <description>Change in gastric emptying time, small bowel transit time, colon transit time and whole gut transit time measured in hours based on a measurement done at baseline and then again at 3 weeks into the intervention within each treatment arm</description>
        <time_frame>21-28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: taken orally for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
          <group group_id="O2">
            <title>Lubiprostone 24 mcg QD</title>
            <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
          <group group_id="O3">
            <title>Lubiprostone 8 mcg BID</title>
            <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline</title>
          <description>Change in gastric emptying time, small bowel transit time, colon transit time and whole gut transit time measured in hours based on a measurement done at baseline and then again at 3 weeks into the intervention within each treatment arm</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gastric emptying time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" spread="13.77"/>
                    <measurement group_id="O2" value="6.52" spread="15.33"/>
                    <measurement group_id="O3" value="-0.16" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small bowel transit time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.04"/>
                    <measurement group_id="O2" value="0.15" spread="1.78"/>
                    <measurement group_id="O3" value="-0.001" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon transit time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="21.23"/>
                    <measurement group_id="O2" value="-4.43" spread="44.6"/>
                    <measurement group_id="O3" value="2.59" spread="31.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole gut transit time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.32" spread="27.3"/>
                    <measurement group_id="O2" value="-1.74" spread="42.67"/>
                    <measurement group_id="O3" value="1.67" spread="29.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Small Bowel pH and Colon pH From Baseline</title>
        <description>Change in the mean pH of the small intestine and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.</description>
        <time_frame>21-28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: taken orally for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
          <group group_id="O2">
            <title>Lubiprostone 24 mcg QD</title>
            <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
          <group group_id="O3">
            <title>Lubiprostone 8 mcg BID</title>
            <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Small Bowel pH and Colon pH From Baseline</title>
          <description>Change in the mean pH of the small intestine and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.</description>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Small bowel pH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.37"/>
                    <measurement group_id="O2" value="0.23" spread="0.36"/>
                    <measurement group_id="O3" value="0.24" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon pH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.50"/>
                    <measurement group_id="O2" value="-0.07" spread="0.45"/>
                    <measurement group_id="O3" value="0.27" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Motility Pattern of the Small Bowel and Colon From Baseline as Defined by the Motility Index</title>
        <description>Change in the motility index defined as the natural log [(sum of pressure amplitudes times the number of contractions) + 1] for the small bowel and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.</description>
        <time_frame>21-28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: taken orally for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
          <group group_id="O2">
            <title>Lubiprostone 24 mcg QD</title>
            <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
          <group group_id="O3">
            <title>Lubiprostone 8 mcg BID</title>
            <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Motility Pattern of the Small Bowel and Colon From Baseline as Defined by the Motility Index</title>
          <description>Change in the motility index defined as the natural log [(sum of pressure amplitudes times the number of contractions) + 1] for the small bowel and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Small bowel motility index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="1.37"/>
                    <measurement group_id="O2" value="-0.01" spread="1.89"/>
                    <measurement group_id="O3" value="0.6" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon motility index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="1.96"/>
                    <measurement group_id="O2" value="-1.32" spread="1.97"/>
                    <measurement group_id="O3" value="0.17" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: taken orally for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
        <group group_id="E2">
          <title>Lubiprostone 24 mcg QD</title>
          <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
        <group group_id="E3">
          <title>Lubiprostone 8 mcg BID</title>
          <description>Lubiprostone: lubiprostone taken either at a dose of 8 mcg orally twice daily for 28 days or 24 mcg orally once daily for 28 days&#xD;
Smartpill wireless motility capsule: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>brief hospitalization for dehydration and disorientation at end of treatment phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Episode of atrial fibrillation spontaneously resolving</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a small study with wide variability among participants, so data should be interpreted with great caution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Richard J Saad</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-936-4780</phone>
      <email>rsaad@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

